Generating overseas sales and other revenue outside the door-to-door sales business
First written in FY2023. 3 of 8 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 13 of 73 companies on the "Worse" side.
3 other companies' latest entry also says "Softened".
- FY2026SoftenedAnnual report
「We currently export the hair-growth product Stem Signal to Taiwan as part of our overseas operations, but have made no exports since August 2023. We plan to increase the number of destination countries in the future.」
The company states that it continues to pursue expansion of overseas sales as a revenue source outside its door-to-door sales business, but has had no results from exports to Taiwan since August 2023. - 2026-06-04RestatedGeneral Meetings of Shareholders
「We will also promote the generation of sales outside the door-to-door sales business, including overseas sales and the promotion of patent licensing.」
The company reaffirmed its policy of promoting overseas sales and patent licensing as sources of revenue outside its door-to-door sales business. - FY2025RestatedAnnual report
「We will also promote the generation of sales from overseas sales and businesses other than the door-to-door sales business.」
The company continues its policy of generating revenue from sources outside its door-to-door sales business, including exports to Taiwan. - FY2024RestatedAnnual report
「We currently export the hair-growth product Stem Signal to Taiwan as part of our overseas operations, with exports having begun in August 2023. We plan to gradually increase the number of destination countries.」
The company has reaffirmed its policy of continuing exports to Taiwan as a revenue source outside its door-to-door sales business and seeking to expand the destination countries for its exports. - FY2024-Q3Exports to Taiwan continue, while exports to Hong Kong remain stalledAnnual report
「Regarding overseas operations, exports to Taiwan of the quasi-drug hair-growth product Medicinal Scalp Care Stem Signal began in August. Revenue for the first nine months was ¥144 thousand, and we expect revenue to grow going forward. Meanwhile, exports to Hong Kong have not progressed, partly due to the impact of the treated water issue at Fukushima Daiichi Nuclear Power Station.」
The company continued exports to Taiwan, recording ¥144 thousand in sales on a cumulative basis through the third quarter, while exports to Hong Kong have not progressed due to external factors. - FY2024-Q2AdvancedAnnual report
「Regarding overseas operations, exports to Taiwan of the quasi-drug hair-growth product Medicinal Scalp Care Stem Signal began in August. Revenue for the first six months was ¥144 thousand, and we expect revenue to grow going forward. We are also preparing to begin exports to Hong Kong shortly.」
Overseas sales have progressed from the preparation-complete stage to the start of exports to Taiwan, recognition of ¥144 thousand in sales and preparations for exports to Hong Kong. - FY2024-Q1AdvancedAnnual report
「Regarding overseas operations, preparations have been completed, and shipments are scheduled to begin from the second quarter onward,」
Overseas sales have progressed from the preparation-complete stage to planned shipments from the second quarter onward. - FY2023First statedAnnual report
「We will also promote the generation of sales from overseas sales and businesses other than the door-to-door sales business.」
The company has stated a new policy of generating sales from overseas sales and other sources as revenue streams outside its domestic door-to-door sales business.